Recombinant monoclonal antibody to IL13. Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.
Figure 1 Tralokinumab prevents IL-13 from interacting with both (a) IL-13Rα1 and (b) IL-13Rα2.
Data are shown as mean % DeltaF (standard error of the mean) from two independent experiments each performed in duplicate.
Popovic, B., Breed, J., Rees, D. G., Gardener, M. J., Vinall, L. M. K., Kemp, B., ... & Colice, G. (2017). Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. Journal of molecular biology, 429(2), 208-219.
Figure 2 Overall structure of the tralokinumab:IL-13 complex.
Heavy chain (VH) is coloured in dark blue, light chain (VL) is coloured in light blue, and IL-13 is shown in purple. Helices A–D of IL-13 are also labelled.
Popovic, B., Breed, J., Rees, D. G., Gardener, M. J., Vinall, L. M. K., Kemp, B., ... & Colice, G. (2017). Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13Rα1 and IL-13Rα2. Journal of molecular biology, 429(2), 208-219.
Figure 3 Neutralization of fibroblast-derived IL-13 inhibits lung fibrosis in an established fibroblast-driven disease setting in humanized SCID mice.
(A–C)Isolated IPF fibroblasts (n= 5) or normal lung tissue fibroblasts (n= 5) were injected intravenously to SCID mice, and animals were killed at specificsubsequent time points. Whole lung mRNA expression was measured by quantitative RT-PCR for il-13 (A), il113ra1(B), and il-13ra2(C) and normalized tolung mRNA expression levels from mice that had received normal lung tissue-derived fibroblasts. (D–N) Thirty-five days after IPF fibroblast engraftment,mice were randomized and treated with PBS control, control IgG4, or tralokinumab (anti–IL-13 mAb) every other day until analysis at Day 63.Representative mouse lung sections stained with Masson's trichrome to depict the degree of fibrosis at Day 63 from SCID/IPF mice treated with PBScontrol (D), CAT251 IgG4isotype control (E), and tralokinumab anti–IL-13 antibody (F). Fibrosis was quantitated in all animals using a modifiedAshcroft score of histological sections (G). Tralokinumab attenuated serum CC16 levels as measured by ELISA (H) and BAL caspase 3 activity (I). Data aremean 6SEM (n= 5). (J–M) Representative immunohistochemistry localizing IL-13Ra2 expression in the lungs of control SCID mice that have notreceived IPF fibroblast (J) or SCID/IPF mice treated with PBS control (K), isotype control (L), or tralokinumab (M). Original magnification: top panels,340;bottom panels,3200. *p<0.05, **p<0.01, and ***p<0.005.
Murray, L. A., Zhang, H., Oak, S. R., Coelho, A. L., Herath, A., Flaherty, K. R., ... & Sleeman, M. A. (2014). Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. American journal of respiratory cell and molecular biology, 50(5), 985-994.
Figure 4 Enhanced epithelial markers in the lungs of SCID/IPF mice treated with tralokinumab.
Whole lung mRNA expression from mice treated withisotype control or tralokinumab (anti–IL-13) was measured using quantitative RT-PCR. Levels of vimentin (A), TGF-b1(B), surfactant protein a (C),surfactant protein b (D), surfactant protein c (E), surfactant protein d (F), and e-cadherin (G) were quantitated and normalized to lung mRNA expressionlevels from SCID/IPF mice that had received PBS control only. Data are mean 6SEM (n= 5). *p<0.05.
Murray, L. A., Zhang, H., Oak, S. R., Coelho, A. L., Herath, A., Flaherty, K. R., ... & Sleeman, M. A. (2014). Targeting interleukin-13 with tralokinumab attenuates lung fibrosis and epithelial damage in a humanized SCID idiopathic pulmonary fibrosis model. American journal of respiratory cell and molecular biology, 50(5), 985-994.
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Afuco™ Anti-IL13 ADCC Recombinant Antibody (Tralokinumab), ADCC EnhancedThis product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to IL13. Tralokinumab is a human monoclonal antibody which targets the cytokine interleukin 13, and is designed for the treatment of asthma and inflammatory diseases.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-219 | Anti-Human IL13 Recombinant Antibody (Lebrikizumab) | ELISA, Neut, IF, IP, FC, FuncS | IgG4 - kappa |
TAB-043ZJ-F(E) | Anti-Human IL-13 Recombinant Antibody Fab Fragment (Lc6Hc2) | ELISA | Humanized antibody |
TAB-044ZJ-F(E) | Human Anti-IL13 Recombinant Antibody; Fab Fragment (TAB-044ZJ-F(E)) | ELISA, Neut | Humanized Fab |
TAB-045ZJ-F(E) | Human Anti-IL13 Recombinant Antibody; Fab Fragment (TAB-045ZJ-F(E)) | ELISA, Block | Humanized Fab |
TAB-046ZJ-F(E) | Human Anti-IL13 Recombinant Antibody; Fab Fragment (TAB-046ZJ-F(E)) | ELISA, Block | Humanized Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
PSBL-600 | Human Anti-IL13 Recombinant Antibody (clone H2L6); scFv Fragment | ELISA | Humanized scFv |
PSBL-601 | Mouse Anti-IL13 Recombinant Antibody (clone X836); scFv Fragment | WB, ELISA, FuncS | Mouse scFv |
HPAB-1739-FY-F(E) | Mouse Anti-IL13 Recombinant Antibody (clone mAb13.2); scFv Fragment | Inhib, ELISA | Mouse scFv |
HPAB-1740-FY-F(E) | Mouse Anti-IL13 Recombinant Antibody (clone ch13.2); scFv Fragment | Inhib, ELISA | Mouse scFv |
HPAB-1741-FY-F(E) | Human Anti-IL13 Recombinant Antibody (clone h13.2v1); scFv Fragment | Inhib, ELISA | Humanized scFv |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-022ZJ | Anti-Human IL-13 Recombinant Antibody (C836) | ELISA | |
TAB-023ZJ | Mouse Anti-IL13 Recombinant Antibody (TAB-023ZJ) | ELISA, Block | Mouse IgG |
TAB-022ZJ-S(P) | Anti-Human IL-13 Recombinant Antibody scFv Fragment (C836) | ELISA | |
TAB-023ZJ-S(P) | Mouse Anti-IL13 Recombinant Antibody; scFv Fragment (TAB-023ZJ-S(P)) | ELISA, Block | Mouse scFv |
TAB-022ZJ-F(E) | Anti-Human IL-13 Recombinant Antibody Fab Fragment (C836) | ELISA |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-094ZJ | Anti-Human IL-13 Recombinant Antibody (167) | ELISA | Chimeric antibody (mouse/human) |
TAB-094ZJ-S(P) | Anti-Human IL-13 Recombinant Antibody scFv Fragment (167) | ELISA | Chimeric antibody (mouse/human) |
TAB-094ZJ-F(E) | Anti-Human IL-13 Recombinant Antibody Fab Fragment (167) | ELISA | Chimeric antibody (mouse/human) |
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-067ZJ-S(P) | Anti-Human IL-13 Recombinant Antibody scFv Fragment (CNTO 607) | ELISA, Inhib | Human antibody |
TAB-068ZJ-S(P) | Anti-Human IL-13 Recombinant Antibody scFv Fragment (01471/G6) | ELISA, Neut | Human antibody |
TAB-069ZJ-S(P) | Human Anti-IL13 Recombinant Antibody; scFv Fragment (TAB-069ZJ-S(P)) | ELISA, Neut, FC | Human scFv |
TAB-070ZJ-S(P) | Human Anti-IL13 Recombinant Antibody; scFv Fragment (TAB-070ZJ-S(P)) | ELISA, Neut, FC | Human scFv |
TAB-017ML | Anti-Human IL13 Recombinant Antibody (Dectrekumab) | ELISA, IHC, FC, IP, IF, Inhib | IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-0781CT | Recombinant Mouse anti-Human IL13 Monoclonal antibody (43227.22) | ELISA, Neut, WB | |
HPAB-0045LY | Human Anti-IL13 Recombinant Antibody (clone IMA-026) | WB, ELISA, FC, IF | Humanized IgG1 |
FN-189CQ | Rat Anti-Il13 Recombinant Antibody (clone CBL-1328) | FuncS, Neut, Block | Rat IgG1, κ |
FN-190CQ | Rat Anti-Il13 Recombinant Antibody (clone CBL-1329) | ELISA, FuncS, FC | Rat IgG1, κ |
HPAB-0355-WJ | Human Anti-IL13 Recombinant Antibody (clone 13C5.5) | ELISA, Neut, FuncS | Humanized IgG1, κ |
CAT | Product Name | Application | Type |
---|---|---|---|
NEUT-1171CQ | Mouse Anti-IL13 Recombinant Antibody (clone B-B13) | ELISA, ELISPOT, Neut | Mouse IgG1 |
NEUT-1172CQ | Mouse Anti-IL13 Recombinant Antibody (clone 10X28) | Neut, WB | Mouse IgG1 |
NEUT-1173CQ | Mouse Anti-IL13 Recombinant Antibody (clone 15H10) | Neut | Mouse IgG2b |
NEUT-1174CQ | Mouse Anti-IL13 Recombinant Antibody (clone 32116.11) | ELISA, Neut, WB | Mouse IgG1 |
NEUT-1175CQ | Rat Anti-IL13 Recombinant Antibody (clone 5A2) | Neut | Rat IgG1 |
CAT | Product Name | Application | Type |
---|---|---|---|
MOR-1790 | Rabbit Anti-IL13 Recombinant Antibody (clone DS1790AB) | WB, ICC, FC, IP | Rabbit IgG |
MOR-4610 | Rabbit Anti-IL13 Recombinant Antibody (clone TH123DS) | WB | Rabbit IgG |
CAT | Product Name | Application | Type |
---|---|---|---|
HPAB-0226CQ-F(E) | Human Anti-IL13 Recombinant Antibody; Fab Fragment (HPAB-0226CQ-F(E)) | ELISA, Neut, FC, FuncS | Human Fab |
HPAB-0227CQ-F(E) | Human Anti-IL13 Recombinant Antibody; Fab Fragment (HPAB-0227CQ-F(E)) | ELISA, Neut, FC, FuncS | Human Fab |
HPAB-0228CQ-F(E) | Mouse Anti-IL13 Recombinant Antibody (clone MJ2-7); Fab Fragment | ELISA, FC, Neut | Mouse Fab |
HPAB-0229CQ-F(E) | Human Anti-IL13 Recombinant Antibody (clone huMJ2-7); Fab Fragment | ELISA, FC, Neut | Humanized Fab |
HPAB-0230CQ-F(E) | Mouse Anti-IL13 Recombinant Antibody (clone C65); Fab Fragment | ELISA, FC, Neut | Mouse Fab |
CAT | Product Name | Application | Type |
---|---|---|---|
AFC-TAB-H05 | Afuco™ Anti-IL13 ADCC Recombinant Antibody (Anrukinzumab), ADCC Enhanced | FC, IP, ELISA, Neut, FuncS, IF | ADCC enhanced antibody |
AFC-TAB-017ML | Afuco™ Anti-IL13 ADCC Recombinant Antibody (Dectrekumab), ADCC Enhanced | ELISA, IHC, FC, IP, IF, Inhib | ADCC enhanced antibody |
AFC-TAB-219 | Afuco™ Anti-IL13 ADCC Recombinant Antibody (Lebrikizumab), ADCC Enhanced | ELISA, Neut, IF, IP, FC, FuncS | ADCC enhanced antibody |
AFC-TAB-218 | Afuco™ Anti-IL13 ADCC Recombinant Antibody (Tralokinumab), ADCC Enhanced | ELISA, FC, IP, FuncS, IF, Neut | ADCC enhanced antibody |
There are currently no Customer reviews or questions for TAB-218. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.